Comprehensive vaccine design for commensal disease progression

Friday, October 20th, 2017

On October 18th, Abcombi Biosciences published an article in Science Advances titled “Comprehensive vaccine design for commensal disease progression”. In this article, we present our unique vaccine formulation strategy for invoking a powerful immune response against polysaccharide antigens without requiring complex chemistry. Using this technology, we prevent colonization by 20 of the most pathogenic pneumococcal strains and provide protection against >70 strains conditioned for virulence.

To read more, please vist:

http://advances.sciencemag.org/content/3/10/e1701797.full

Abcombi BioSciences Inc

Abcombi Biosciences Inc (ABI) is a preclinical-stage biotechnology company founded upon technological breakthroughs developed at the State University of New York at Buffalo (University at Buffalo).